{
  "id": 20618178,
  "title": "Relay Therapeutics at Jefferies: cash, trials and a dual-track push",
  "url": "https://urgent.news/2026/11/18/relay-therapeutics-at-jefferies-cash-trials-and-a-dual-track-push",
  "topic": "culture",
  "section": "Culture",
  "published": "2026-11-18T16:10:20.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/relay-therapeutics-at-jefferies-cash-trials-and-a-dualtrack-push-93CH-5036631"
  },
  "original_language": "en",
  "account": "On Wednesday, 18 November 2026, Relay Therapeutics (RLAY) utilized the Jefferies Global Healthcare Conference to present a comprehensive development plan centered around zovegalisib, its PI3Kα mutant-selective drug candidate. The company highlighted robust clinical progress, a substantial cash reserve of $849 million, and a growing commercial infrastructure, while acknowledging that future value would hinge on ongoing trial execution and regulatory approvals. RLAY disclosed that it possesses $849 million in cash reserves, sufficient to sustain operations through 2029 and support several major data presentations. The lead asset, zovegalisib, is currently advancing through three pivotal trials, notably a second-line breast cancer study that is enrolling participants faster than anticipated. In vascular anomalies, the drug demonstrated a 60% response rate, significantly surpassing the current standard of care's 17% to 27% response rate, with further data expected in December 2026. The company is simultaneously developing commercial capabilities for both the breast cancer and rare disease markets, while keeping the door open to potential partnerships and mergers and acquisitions. Besides zovegalisib, Relay Therapeutics is also investigating an NRAS-selective inhibitor for potential use in melanoma, colorectal cancer, and other solid tumors, adding another dimension to its long-term value creation strategy.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}